Statera Biopharma Submits Pilot Study to U.S. FDA
Statera Biopharma, Inc. (Nasdaq: STAB) recently announced that it submitted a pilot study protocol for STAT-205 treatment of post-acute COVID-19 to the U.S. Food and Drug Administration (FDA). Pilot Program The Phase 1 pilot study is set to evaluate the...